INVITATION

University Hospital Regensburg
KUNO Children’s Hospital
Department of Pediatric Hematology, Oncology and Stem Cell Transplantation

3rd International Meeting of the Sickle Cell Disease Cure and Prevention Consortium (SCDC)
June 25th and 26th, 2015
Universitätsklinikum Regensburg

FINAL PROGRAM

Scientific Leadership
Prof. Dr. Selim Corbacioglu
Professor of Pediatrics
KUNO Children’s Hospital
University Hospital Regensburg

Congress Venue
Hotel Goldenes Kreuz „Kaisersaal”
Haidplatz 7, 93047 Regensburg, Germany

Congress Management
Congress Division UK3, Britta Haseneder
University Hospital Regensburg
93042 Regensburg, Germany
Phone: +49 941 944-4230
Fax: +49 941 944-4233
E-mail: kongresse@ukr.de

Registration
Online registration under:
www.congress-registration.ukr.de

Congress Fee
Both days  100 €
Conference Dinner  50 €

Registration conditions
After your successful registration you will receive an invoice concerning your participation fee during the next days by email. Once registered your registration is binding. All payments must be made prior to the conference. Participation fees are due upon receipt of invoice without deduction. Please transfer the invoice amount before the event date. In case of a cancellation the cancellation statement must be in writing. The following processing fees apply: 8-3 working days before the event 50% of participation fee. In case of too late cancellation or absence without written cancellation the entire fee will be charged. A substitute participant may be submitted at any time. The conference will be certified with training points by the Bavarian Medical Association.

Sponsors
Astellas Pharma GmbH  1.300 €
Gilead Sciences GmbH  1.500 €
Jazz  5.000 €
Medac GmbH  3.000 €
Miltenyi Biotec GmbH  2.000 €
MSD Sharp & Dohme GmbH  1.000 €
Novartis Pharma GmbH  2.500 €

We thank all sponsors of the conference for their kind support. Sponsoring performance for booth fee and advertising purposes.

Supported by a grant of the Helga and Erwin Hartl Stiftung

General Information

Speakers

Nosa Bazuaye
University of Benin, Stem cell Transplant Centre
Benin, NIGERIA

Françoise Bernaudin
Centre Hospitalier Intercommunal
 Créteil, FRANCE

Marina Cavazzana-Calvo
Département de Biothérapie Institut IMAGINE
Paris, FRANCE

Fabio Ciceri, MD
San Raffaele Scientific Institute
Milan, ITALY

Selim Corbacioglu
KUNO Children’s Hospital, University Hospital Regensburg
GERMANY

Kenneth Enwerem
Omega Cares Foundation
NIGERIA

Lawrence Faulkner
Cure2Children Foundation
ITALY

Elaine Gluckman
University Hospital of Ile-de-France
Paris, FRANCE

Tayfun Güngör
Kinderspital Zürich
SWITZERLAND

Rupert Handgretinger
Children’s Hospital, University of Tübingen
GERMANY

Wolfgang Herr
University Hospital Regensburg
GERMANY

Suradej Hongeng
Mahidol University, Department of Pediatrics, Ramathibodi Hospital
Bangkok, THAILAND

Adetola Kassim
Vanderbilt-Ingram Cancer Center
Nashville, USA

Abel Makubi
Muhimbili University of Health and Allied Sciences (MUHAS)
Dar es Salaam, TANZANIA

Dietger Niederwieser
University Hospital Leipzig
GERMANY

Pieter Sodani
Tor Vergata University
Rome, ITALY

Cornelio Uderzo
Cure2Children Foundation
ITALY

Volker Witt
St Anna’s Kinderspital
Vienna, AUSTRIA

Supported by a grant of the Helga and Erwin Hartl Stiftung
Dear friends and colleagues!

We are happy to invite you to the third “Meeting of the Sickle Cell Disease Cure and Prevention Consortium” in Regensburg on June 25 and 26, 2015.

Mostly due to the lack of a suitable donor sickle cell disease (SCD) remained a medical orphan for transplant physicians up to now. With the substantial advancements in innovative transplant techniques using alternative donors SCD is becoming a curable disease for everybody. Additionally as a monogenetic disease gene therapy for SCD is just around the corner.

The main focus of this meeting is to harmonize standards and criteria and establish a road map for a prospective evaluation of the available modalities of haploidentical SCT for SCD, learn from the standard of care and receive an up-to-date outlook on gene therapy. With that regard this meeting is geared towards the expert in the field of SCT for hemoglobinopathies. It shall also serve as a forum for discussion and networking with colleagues from countries with a high prevalence of SCD in order to improve our understanding.

We are looking forward to welcome you in Regensburg!

With best regards

Prof. Dr. Selim Corbacioglu
Professor of Pediatrics KUNO Children's Hospital
University Hospital Regensburg

---

**Thursday, June 25th, 2015**

**12:00** Registration and Lunch Snack

**12:30** Welcome Reception
Dietger Niederwieser, Selim Corbacioglu

**Session I (Developing Countries)**
Chair: Dietger Niederwieser, Nosa Bazauye

**12:50** Report of hematopoietic SCT for SCD and challenges in a poor resource country Nigeria
Nosa Bazauye

**13:10** Setting up a bone marrow transplant centre in a low resource setting: prospects and challenges
Kenneth Enwerem

**13:30** Treatment options for sickle cell disease: Experience and perspectives from a sickle cell center in Afrika
Abel Makubi

**13:50** Setting up BMT units for hemoglobinopathies in emerging countries: Update of the Cure-2Children Foundation experience
Lawrence Falkner

**14:10** Cooperation of two Italian NGOs in subequatorial areas of Africa at high incidence of „sickle cell disease“: purposes and preliminary results
Cornelio Uderzo

**14:30** Coffee break

**Session II (Standard of care and new concepts for SCT for SCD)**
Chair: Rupert Handgretinger, Adetola Kassim

**15:00** MSD/MUD SCT in Sickle Cell Disease, State of the Art
Françoise Bernaudin

**15:20** International survey on HLA identical sibling hematopoietic stem cell transplantation
Eliane Gluckman

**15:40** Ex-vivo T-cell depletion in allogeneic transplantation for hemoglobinopathies
Rupert Handgretinger

**16:00** Reduced intensity conditioning – how much myeloablative chemo do we need for non-malignant diseases?
Tayfun Gungör

**16:20** Haplo-SCT in SCD with post-transplant Cyclophosphamide
Adetola Kassim

---

**Friday, June 26th, 2015**

**Session III (Gene Therapy)**
Chair: Fabio Ciceri

**08:30** Updated results on gene therapy for hemoglobinopathies
Marina Cavazzano-Calvo

**09:00** Gene therapy in ß-Thalassemias: The first steps
Fabio Ciceri

**09:30** Consensus
Chair: Lawrence Faulkner, Selim Corbacioglu

- Prospective evaluation of haploidentical SCT concepts in a combined registry
- Definition of standards:
  - Indications for Haplo-SCT in 2015
  - Preparative regimens prior to SCT (Immunosuppression, exchange TF, etc.)
  - Conditioning regimens
  - Immunosuppressive therapy
  - Indicative outcome parameters to compare both haplo-SCT approaches
- Et al.

**12:30** Lunch at Lepanto Lounge